medigraphic.com

2007, Number 2

<< Back Next >>

Bioquimia 2007; 32 (2)

Chronic inflammation and oxidative stress in diabetes mellitus

Rosado-Pérez J, Mendoza-Núñez VM

Language: Spanish
References: 69
Page: 58-69
PDF size: 161.22 Kb.


ABSTRACT

Diabetes mellitus is a metabolic disease of endocrine system, which its biochemical disturbance main is a chronic hyperglycemia associated to failures in the action and/or production of insulin, with alterations in the metabolism of lipids and proteins. In this sense, it has been showed that chronic hyperglycemia is the etiologic factor more relevant of the diabetic complications; however the biochemical mechanisms involved in the physiopathologic process are not perfectly known. In such regard, it has been hypothesized that the hyperglycemia promotes biochemical disturbances that forward injury to the organism, such as oxidative stress and chronic inflammatory process. Therefore, in this review are analyzed these mechanisms, besides we show the scientific evidences that support this proposal.


REFERENCES

  1. Secretaría de Salud Modificación a la Norma Oficial Mexicana, NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria. México D.F.: Diario Oficial de la Federación, 7 de abril 2000.

  2. Medina-Gómez G, Lelliot C, Vidal-Puig A. Lipotoxicidad y diabetes. Scient Am Latinoam. 2002; 58-65.

  3. Moreno AL. Epidemiología y diabetes. Rev Fac Med UNAM. 2001; 44: 35-37.

  4. Zimmet P, Boyko E, Collier GR, Courten M. Ethiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance and other players. Ann NY Acad Sci. 2001; 30: 25-44.

  5. Secretaría de Salud. Estadísticas de mortalidad en México. Muertes registradas en 2001. Salud Pública Mex. 2002; 44: 565-581.

  6. Olaiz G, Rojas R, Barquera S, Shaman T, Aguilar C, Cravioto P, López P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Mor; Instituto Nacional de Salud Pública; 2003. p. 94-103.

  7. Secretaría de Salud. Información epidemiológica de morbilidad 2005. Versión ejecutiva. México: Secretaría de Salud; 2006. p. 21.

  8. Bloomgarden ZT. The epidemiology of complications. Diabetes Care. 2002; 25: 924-932.

  9. Pickup JC. Inflammation and activate innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004; 27: 813-823.

  10. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insuline resistance, obesity and diabetes. Trens Immunol. 2004; 25: 4-7.

  11. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000; 408: 239-247.

  12. Bergendi L, Benes L, Duraccik M. Chemistry physiology and pathology of free radicals. Life Sci. 1999; 65: 1865-1874.

  13. Moskovitz J, Yim BM, Chock BP. Free radicals and disease. Arch Biochem Biophys. 2002; 397: 354-359.

  14. Mc Cord J. The evolution of free radicals and oxidative stress. Am J Med. 2000; 108: 652-659.

  15. Johanse SJ, Harris KA, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovas Diabetol 2005; 4: 5-16.

  16. Halliwell B, Gutteridge MC, Cross E. Free radicals, antioxidants and human disease: where are we now? J Lab Clin Med. 1992; 119: 598-620.

  17. Halliwell B. Reactive Oxygen species in living systems: source, biochemistry and role in human disease. Am J Med. 1991; 91: 3C-14S-3C-22S.

  18. González-Torres MC, Betancourt-Rule M, Ortiz-Muñiz R. Daño oxidativo y antioxidantes. Bioquimia. 2000; 25: 3-9.

  19. Halliwell B. The definition and measurement of antioxidants in biological systems. (Letter). Free Radic Biol Med. 1995; 18:125-126.

  20. Niki E. Action of antioxidants against oxidative stress. In: Dizdaroglu M, Katarataya AE (Eds.) Advances in DNA damage and repair. New York: Kluwer Academic/Plenum Publishers. 1999. p. 313-318.

  21. De Zwart LL, Meerman JH, Commandeur JNM, Vermeulen PE. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol & Med. 1999; 26: 202-226.

  22. Rojas E, López MC, Valverde M. Single cell gel electrophoresis assay: methodology and applications. J Cromatogr B. 1999; 722: 225-254.

  23. Sánchez-Rodríguez MA, Santiago-Osorio E, Vargas LA, Mendoza-Núñez VM. Propuesta de un constructo para evaluar integralmente el estrés oxidativo. Bioquimia. 2004; 29: 81-90.

  24. Clapés S, Torres O, Companioni M, Villariño U, Broche F, Céspedes EM. Peroxidación lipídica y otros indicadores de estrés oxidativo en pacientes diabéticos. Rev Cubana Invest Biomed. 2001; 20: 93-98.

  25. Davison G, George L, Jackson SK, Young IS, Davies B, Bailey DM, et al. Exercise, free radicals, and lipid peroxidation in type 1 diabetes mellitus. Free Radic Biol Med. 2002; 33: 1543-1551.

  26. VanderJagt JD, Harrison MJ, Ratliff MD, Hunsaker LA, Vanderjagt LD. Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem. 2001; 34: 265-270.

  27. Varvarovska J, Racek J, Stetina R, Sykora J, Pomahacova R, Rusavy Z, et al. Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother. 2004; 58: 539-545.

  28. Bathia S, Shukla R, Madhu VS, Gambhir KJ, Prabhu MK. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem. 2003; 36: 557-562.

  29. Ziegler D, Sohr CG, Nouroo-Zadeh J. Oxidative stress and antioxidant defence in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004, 27: 2178-2183.

  30. Saxena R, Madhu SV, Shukla R, Prabhu KM, Gambhir JK. Postpandrial hypertriglyceridemia and oxidative stress in patients of type 2 diabetes mellitus with macrovascular complications. Clin Chem Acta. 2005; 359: 101-108.

  31. Sakai K, Matsumoto K, Nishikawa T, Suefuji M, Nakamaru K, Hirashima Y, et al. Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic B-cells. Biochem Biophys Res Comm. 2003; 300: 216-222.

  32. Blanco-Hernández R, Ruiz-Ramos M, Sánchez-Rodríguez MA, Mendoza-Núñez VM. Lipoperóxidos, actividad antioxidante y factores pro-oxidantes en adultos mayores con diabetes mellitus tipo2. Bioquimia. 2004; 29: 118-125.

  33. Villa-Caballero L, Nava-Ocampo A, Ponce-Monter H, Frati-Munari A. El estrés oxidativo. ¿Es necesario medirlo en el paciente diabético? Gac Med Mex. 2000; 136: 249-255.

  34. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003; 216: 1589-1596.

  35. Robertson PR, Harmon J, Tran OP, Tanaka Y, Takahashi H. Glucose toxicity in B-cells: type 2 diabetes, good radicals gone bad, end the glutathione connection. Diabetes 2003; 52: 581-587.

  36. Baynes WJ, Thorpe RS. Role of oxidative stress in diabetic complications. Diabetes. 1999; 48:1-9.

  37. Robertson PR, Harmon J, Tran OP, Poitout V. B-cell glucose toxicity, lipotoxicity and chronic oxidative stress in type 2 diabetes. Diabetes. 2004; 53 (Suppl. 1): S119-124.

  38. Gugliucci A. Glycation as the glucose link to diabetic complications. J Am Osteopath Assoc. 2000; 100: 621-633.

  39. Triana MM. La hiperglucemia y sus efectos tóxicos, un concepto patogénico para la micro y macroangiopatía diabética. Rev Cubana Angiol Vasc. 2001; 2: 131-141.

  40. Koening RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobine A1c in diabetes mellitus. N Engl J Med. 1976; 295: 417-420.

  41. Flecha LG, Castello PR, Gagliardino JJ, Rossi FCJ. La glucosilación no enzimática de proteínas. Mecanismo y papel de la reacción en la diabetes y el envejecimiento. Ciencia al Día Internacional 2000; 3: 1-17.

  42. Vlassara H, Palace MR. Diabetes and advances glycation end-products. J Intern Med. 2002; 251: 87-101.

  43. Evans LJ, Goldfine DA, Maddux AB, Grodsky GM. Are oxidative stress activated signalling pathways mediators of insuline resistance and B-cell dysfunction? Diabetes 2003; 52: 1-8.

  44. Ames NB, Shigenaga KM, Hagen MT. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci. 1993; 90: 7915-7922.

  45. Ble-Castillo JL, Carmona-Díaz E, Méndez JD, Larios-Medina FJ, Medina-Santillán R, Cleva-Villanueva G, et al. Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics. Biomed Pharmacother. 2005; 30.

  46. Berryman AM, Maritim AC, Sanders RA, Watkins JB. Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol. 2004; 18: 345-352.

  47. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999; 257: 251-258.

  48. Punchard NA, Whelan C, Adcock J. The journal of inflammation. [Editorial]. J Inflamm. 2004; 1: 1.

  49. Spector WG, Willoughby DA. The inflammatory response. Bacteriol Rev. 1963; 27: 117-149.

  50. Hamblin S. Cytokines and cytokines receptors. 2nd ed. New York: Irl Press Oxford University; 1993. p. 55-67.

  51. Goldsby RA, Kindt T, Osborne B, Kuby J. Inmunología. México: McGraw-Hill Interamericana; 2004. p. 357-380.

  52. Meager A. The cytocine concept. In: Cytokine. New Jersey: Prentice Hall Advenced Referent Series; 1991. p. 1-19, 158-173.

  53. González-Hita M, Bastidas-Ramírez BE, Ruiz-Madrigal B, Godínez S, Pandero A. Funciones endocrinas de la célula adiposa. Rev Endocrinol Nutr. 2002; 10: 140-146.

  54. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem. 2004; 50: 1511-1525.

  55. Bastarrachea-Sosa R, Laviada-Molina H, Machado-Domínguez I. El eje adipo-pancreático: hacia un nuevo enfoque terapéutico para prevenir la resistencia a la insulina y la diabetes tipo 2. Rev Endocrinol Nutr. 2002; 10: 128-134.

  56. Wiecej A, Kokot F, Chudek J, Adanczak M. The adipose tissue- a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant. 2002; 17: 191-195.

  57. Kiecolt-Glaser J, Preacher JK, MacCallum CR, Atkinson C, Malarkey BW, Glasier R. Chronic stress and age-relates increases in the proinflammatory cytokine IL-6. PNAS. 2003; 100: 9090-9095.

  58. Dinarello AC. Proinflammatory cytokines. Chest. 2000; 118: 503-508.

  59. Wilcox G. Insuline and insuline resistance. Clin Biochem Rev. 2005; 26:19-38.

  60. Cruz M, Velasco E, Kumate J. Señales intracelulares que intervienen el control de la glucosa. Gac Med Méx. 2001; 137: 135-146.

  61. Kahn B, Flier J. Obesity and insuline resistance. J Clin Invest. 2000; 106: 473-481.

  62. Cheng YH, Kim JH, Kim WK, Choi SJ, Yu PB. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech. 2002; 59: 264-272.

  63. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean EJM, Haffner MS. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care. 2002; 25: 2016-2021.

  64. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk C, Tanaka S, Matsuzawa Y, et al. Inflammatory markers, adiponectin and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003; 26: 1745-1751.

  65. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003; 26: 2754-2757.

  66. Spranger J, Kroke A, Möhling M, Hoffman k, Bergmann M, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes. 2003; 52: 812-817.

  67. King D, Mainous A, Buchanan T, Pearson W. C- Reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003; 26:1535-1539.

  68. Hu Bf, Meigs BJ, Li YT, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53: 693-700.

  69. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kB. Diabetes. 2001; 50: 2792-2802.




2020     |     www.medigraphic.com